217 related articles for article (PubMed ID: 24928612)
1. 6-thioguanine: a drug with unrealized potential for cancer therapy.
Munshi PN; Lubin M; Bertino JR
Oncologist; 2014 Jul; 19(7):760-5. PubMed ID: 24928612
[TBL] [Abstract][Full Text] [Related]
2. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Lubin M; Lubin A
PLoS One; 2009 May; 4(5):e5735. PubMed ID: 19478948
[TBL] [Abstract][Full Text] [Related]
3. Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.
Tang B; Testa JR; Kruger WD
Cancer Biol Ther; 2012 Sep; 13(11):1082-90. PubMed ID: 22825330
[TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.
Coulthard SA; Redfern CP; Vikingsson S; Lindqvist-Appell M; Skoglund K; Jakobsen-Falk I; Hall AG; Taylor GA; Hogarth LA
Mol Cancer Ther; 2011 Mar; 10(3):495-504. PubMed ID: 21282358
[TBL] [Abstract][Full Text] [Related]
5. Specific Targeting of
Tang B; Lee HO; An SS; Cai KQ; Kruger WD
Cancer Res; 2018 Aug; 78(15):4386-4395. PubMed ID: 29844120
[TBL] [Abstract][Full Text] [Related]
6. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
Chen ZH; Zhang H; Savarese TM
Cancer Res; 1996 Mar; 56(5):1083-90. PubMed ID: 8640765
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.
Collins CC; Volik SV; Lapuk AV; Wang Y; Gout PW; Wu C; Xue H; Cheng H; Haegert A; Bell RH; Brahmbhatt S; Anderson S; Fazli L; Hurtado-Coll A; Rubin MA; Demichelis F; Beltran H; Hirst M; Marra M; Maher CA; Chinnaiyan AM; Gleave M; Bertino JR; Lubin M; Wang Y
Mol Cancer Ther; 2012 Mar; 11(3):775-83. PubMed ID: 22252602
[TBL] [Abstract][Full Text] [Related]
8. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
Tedeschi PM; Kathari YK; Johnson-Farley N; Bertino JR
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1247-52. PubMed ID: 25917288
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.
Bertino JR; Waud WR; Parker WB; Lubin M
Cancer Biol Ther; 2011 Apr; 11(7):627-32. PubMed ID: 21301207
[TBL] [Abstract][Full Text] [Related]
10. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
[TBL] [Abstract][Full Text] [Related]
12. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
13. Lack of expression of MTAP in uncommon T-cell lymphomas.
Bertino JR; Lubin M; Johnson-Farley N; Chan WC; Goodell L; Bhagavathi S
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):306-9. PubMed ID: 23040436
[TBL] [Abstract][Full Text] [Related]
14. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
[TBL] [Abstract][Full Text] [Related]
15. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
16. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
Chen ZH; Olopade OI; Savarese TM
Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
[TBL] [Abstract][Full Text] [Related]
17. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.
Batova A; Diccianni MB; Nobori T; Vu T; Yu J; Bridgeman L; Yu AL
Blood; 1996 Oct; 88(8):3083-90. PubMed ID: 8874207
[TBL] [Abstract][Full Text] [Related]
18. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
Christopher SA; Diegelman P; Porter CW; Kruger WD
Cancer Res; 2002 Nov; 62(22):6639-44. PubMed ID: 12438261
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Barbarino M; Cesari D; Bottaro M; Luzzi L; Namagerdi A; Bertolino FM; Bellan C; Proietti F; Somma P; Micheli M; de Santi MM; Guazzo R; Mutti L; Pirtoli L; Paladini P; Indovina P; Giordano A
J Cell Mol Med; 2020 May; 24(10):5565-5577. PubMed ID: 32301278
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.
Hustinx SR; Hruban RH; Leoni LM; Iacobuzio-Donahue C; Cameron JL; Yeo CJ; Brown PN; Argani P; Ashfaq R; Fukushima N; Goggins M; Kern SE; Maitra A
Cancer Biol Ther; 2005 Jan; 4(1):83-6. PubMed ID: 15662124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
